Amidst the resounding success of Novo’s SELECT trial, the clinical trial landscape finds itself inundated with a surge of innovative GLP-1 treatments. Each passing week witnesses the unveiling of new multi-million-dollar investments, propelling GLP-1 players to the forefront of pharmaceutical revenue growth.